GLAUKOS CorpGKOSEarnings & Financial Report
Glaukos Corp is a medical technology company focused on ophthalmology, developing and commercializing minimally invasive surgical devices, prescription pharmaceuticals and consumer products for glaucoma, corneal diseases and other eye disorders. It operates primarily across North America, Europe and Asia Pacific, serving hospitals, ophthalmology clinics and patients worldwide.
GKOS Q4 2025 Key Financial Metrics
Revenue
$143.1M
Gross Profit
$-1.5M
Operating Profit
$-139.9M
Net Profit
$-133.7M
Gross Margin
-1.1%
Operating Margin
-97.7%
Net Margin
-93.4%
YoY Growth
35.7%
EPS
$-2.34
Financial Flow
GLAUKOS Corp Q4 2025 Financial Summary
GLAUKOS Corp reported revenue of $143.1M (up 35.7% YoY) for Q4 2025, with a net profit of $-133.7M (down 298.0% YoY) (-93.4% margin). Cost of goods sold was $144.6M, operating expenses totaled $138.4M.
Key Financial Metrics
| Total Revenue | $143.1M |
|---|---|
| Net Profit | $-133.7M |
| Gross Margin | -1.1% |
| Operating Margin | -97.7% |
| Report Period | Q4 2025 |
Revenue Breakdown
GLAUKOS Corp Q4 2025 revenue of $143.1M breaks down across 3 segments, led by Glaucoma at $86.4M (60.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Glaucoma | $86.4M | 60.3% |
| Other | $35.1M | 24.5% |
| Corneal Health | $21.6M | 15.1% |
GLAUKOS Corp Revenue by Segment — Quarterly Trend
GLAUKOS Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Glaucoma and Other) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Glaucoma | $86.4M | $80.8M | $72.3M | $59.1M |
| Other | $35.1M | $32.1M | $33.6M | $31.6M |
| Corneal Health | $21.6M | $20.6M | $18.2M | $15.9M |
GLAUKOS Corp Annual Revenue by Year
GLAUKOS Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $507.4M). Click any linked year to see what changed vs the prior annual report.
GLAUKOS Corp Quarterly Revenue & Net Profit History
GLAUKOS Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $143.1M | +35.7% | $-133.7M | -93.4% |
| Q3 2025 | $133.5M | +38.1% | $-16.2M | -12.2% |
| Q2 2025 | $124.1M | +29.7% | $-19.7M | -15.8% |
| Q1 2025 | $106.7M | +24.6% | $-18.1M | -17.0% |
| Q4 2024 | $105.5M | +28.1% | $-33.6M | -31.8% |
| Q3 2024 | $96.7M | +23.9% | $-21.4M | -22.1% |
| Q2 2024 | $95.7M | +19.0% | $-50.5M | -52.8% |
| Q1 2024 | $85.6M | +15.9% | $-40.8M | -47.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $85.6M | $95.7M | $96.7M | $105.5M | $106.7M | $124.1M | $133.5M | $143.1M |
| YoY Growth | 15.9% | 19.0% | 23.9% | 28.1% | 24.6% | 29.7% | 38.1% | 35.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $933.3M | $919.7M | $926.5M | $974.8M | $966.2M | $987.0M | $999.4M | $893.5M |
| Liabilities | $482.6M | $254.5M | $258.0M | $207.8M | $202.2M | $221.8M | $229.8M | $237.3M |
| Equity | $450.7M | $665.2M | $668.5M | $766.9M | $764.0M | $765.1M | $769.5M | $656.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-33.9M | $-18.4M | $-9.6M | $507000 | $-18.5M | $7.0M | $-10.1M | $6.8M |